Search

Displaying results 5251 - 5260 of 7181 in total
  1. Drug

    Trapidil

    go.drugbank.com/drugs/DB09283
    Experimental

    Trapidil, a platelet-derived growth factor antagonist, was originally developed as a vasodilator and anti-platelet agent and has been used to treat patients with ischemic coronary heart, liver, and kidney

  2. Drug

    Sarafloxacin

    go.drugbank.com/drugs/DB11491
    ApprovedVet approvedWithdrawn

    Sarafloxacin is a quinolone antibiotic drug, which was discontinued by its manufacturer, Abbott Laboratories, before receiving approval for use in the US or Canada.

  3. Drug

    Pazopanib

    go.drugbank.com/drugs/DB06589
    ApprovedInvestigational

    It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.

  4. Drug

    Anumigilimab

    go.drugbank.com/drugs/DB16359
    Investigational

    CSL324 is a fully human anti-G-CSFR antibody shown to have the ability to control G-CSF-mediated neutrophilia in cynomolgus macaques.

  5. Drug

    AG-858

    go.drugbank.com/drugs/DB05502
    Investigational

    Tumor-derived HSP70-peptide complexes used in vaccine preparations have been shown to prime tumor immunity and tumor-specific T cells in animal models.

  6. Drug

    Proscillaridin

    go.drugbank.com/drugs/DB13307
    Experimental

    Proscillaridin is a cardiac glycoside that is derived from plants of the genus Scilla and in Drimia maritima (Scilla maritima).

  7. Drug

    beta-Alanine

    go.drugbank.com/drugs/DB03107
    Investigational

    Since neuronal uptake and neuronal receptor sensitivity to beta-alanine have been demonstrated, the compound may be a false transmitter replacing GAMMA-AMINOBUTYRIC ACID. … beta-Alanine is an amino acid formed in vivo by the degradation of [dihydrouracil] and [carnosine].

  8. Drug

    4'-Methylene-5,8,10-trideazaaminopterin

    go.drugbank.com/drugs/DB05616
    Investigational

    CH-1504 is a an antirheumatic agent that has been shown in vitro to be a nonpolyglutamylatable and nonhydroxylatable antifolate that is more efficiently taken up into cells by the reduced folate carrier

  9. Drug

    Efavaleukin alfa

    go.drugbank.com/drugs/DB16149
    Investigational

    Efavaleukin alfa is a fusion protein consisting of interleukin mutein fused to the C-terminus of an immunoglobulin G Fc domain by way of a G4S linker.

  10. Drug

    Elacridar

    go.drugbank.com/drugs/DB04881
    Investigational

    Development is assumed to have been discontinued. … In many cases, the appearance of multidrug resistance in cancer is due to a change in expression of protein inhibitors. As of August 2007 elacridar was not listed on GSK's product pipeline.